<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The in vitro synthesis of <z:chebi fb="0" ids="15647">leukotriene B4</z:chebi> (<z:chebi fb="0" ids="15647">LTB4</z:chebi>) was evaluated in colorectal biopsy specimens and resection tissue from patients with <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The in vitro formation of <z:chebi fb="0" ids="15647">LTB4</z:chebi> from biopsy tissues stimulated with <z:chebi fb="0" ids="22986">calcium ionophore</z:chebi> A23187 correlated with the degree of mucosal <z:mp ids='MP_0001845'>inflammation</z:mp> assessed at sigmoidoscopy, and with neutrophil infiltration measured as myeloperoxidase activity </plain></SENT>
<SENT sid="2" pm="."><plain>Biopsy specimens from patients taking <z:chebi fb="2" ids="8378">prednisolone</z:chebi> formed less <z:chebi fb="0" ids="15647">LTB4</z:chebi> than those from patients not on <z:chebi fb="2" ids="8378">prednisolone</z:chebi>, with comparable levels of <z:mp ids='MP_0001845'>inflammation</z:mp> seen at sigmoidoscopy </plain></SENT>
<SENT sid="3" pm="."><plain>The formation of <z:chebi fb="0" ids="15647">LTB4</z:chebi> was reduced dose-dependently by the <z:chebi fb="0" ids="27777">acetohydroxamic acid</z:chebi> 5-<z:chebi fb="0" ids="35856">lipoxygenase inhibitor</z:chebi> BWA4C, with no significant inhibition of <z:chebi fb="0" ids="15551">prostaglandin E2</z:chebi> or <z:chebi fb="0" ids="28728">thromboxane B2</z:chebi> synthesis </plain></SENT>
<SENT sid="4" pm="."><plain>In inflamed colonic resection tissue from colitic patients, the IC50 for inhibition of <z:chebi fb="0" ids="15647">LTB4</z:chebi> formation by BWA4C was 0.03 mumol/l, compared with an IC50 of 0.8 mumol/l for NDGA </plain></SENT>
<SENT sid="5" pm="."><plain>Thus, BWA4C is a potent and selective inhibitor of <z:chebi fb="0" ids="15647">LTB4</z:chebi> synthesis in colonic tissue from patients with <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="27777">Acetohydroxamic acid</z:chebi> 5-<z:chebi fb="0" ids="35856">lipoxygenase inhibitors</z:chebi>, exemplified by BWA4C, may be useful to evaluate the clinical importance of <z:chebi fb="0" ids="15647">LTB4</z:chebi> in <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo>, and offer a novel therapy for the disease </plain></SENT>
</text></document>